Skip to Content
Merck
HomeServicesBioReliance® Contract TestingFinal Product Release TestingmAbs Final Product Release Testing

mAbs Final Product Release Testing

GMP biosafety testing for mAb product release

Every lot of monoclonal antibodies produced for preclinical and clinical studies requires a series of tests to ensure that active ingredients are free of contaminants according to 21 CFR 211.165 and 21 CFR 610. Our comprehensive spectrum of cGMP-compliant final product testing services provides assurance of patient safety and regulatory compliance in any geography, with service provision on three continents and backup facilities to ensure continuity of supply. 

You can rely on our knowledge, capabilities, and vision with complete confidence at any stage of the biomanufacturing process. Our recommended final product release testing services include:

  • Sterility by membrane filtration
  • Sterility by direct inoculation (14 day Sterility)
  • Endotoxin (LAL)
  • Characteristics of the final product

To discuss your final product release testing needs, use our reply form and get in touch today.

Related Product Literature

Flyer: Comprehensive Lot Release Testing

Request Information

Related Applications
Monoclonal Antibody Manufacturing
Monoclonal antibody manufacturing requires scalable solutions ensuring high therapeutic concentration and process safety for immunotherapy.
Related Services
Raw Material Testing
Our raw material testing helps ensure the quality and purity of materials used in biologics production.
Viral Clearance Testing
Viral Clearance studies are critical to the validation of downstream processes, ensuring viral clearance process steps are effective and reproducible in the biopharma manufacturing setting.
mAbs Bulk Harvest Release Testing
Bulk harvest testing for mAbs ensures cGMP compliance, addressing purity, potency, identity, residuals, and sterility.
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?